Access to Medicine

Update: Global Fund responds to Report on William Steiger

Posted on by Thiru

The Global Fund just sent an email, which says that “your website which inaccurately reports that Mr Steiger will run VPP.” Here is the Global Fund email:

From: Andrew Hurst
Date: June 20, 2012 5:36:49 PM GMT+02:00
To: Thirukumaran Balasubramaniam Subject: RE: Question on the Global Fund’s Voluntary Pooled Procurement?

Dear Thiru

Further to our conversation this week, here is our statement:

Continue Reading →

1

Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health

Posted on by James Love

Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health (Copy of US statement available here: https://www.keionline.org/node/1416).

May 25, 2012

To each and everyone who worked on the SCP submission:

This letter outlines our concerns to the May 23, 2012 statement to the 18th Session of the World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (SCP), on the agenda for patents and health.

In its opening, the USPTO said the following:

Continue Reading →

1

US statement to SCP 18 on the United States proposal on Patents and Health

Posted on by James Love

The following is the statement read today by USPTO during a meeting of the WIPO Standing Committee on the Law of Patent, on the agenda item for patents and health. I’ll provide more commentary later, but in general, this was seen an aggressive attack on a proposal for work by the Development Agenda Group (DAG), and on the notion that countries should grant compulsory licenses on patents to address concerns over access or affordability of drugs.

[Update: KEI wrote to USPTO about the submission: /node/1420]

The USPTO statement follows:

SCP18

Continue Reading →

1

KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)

Posted on by James Love

The India Controller General Controller General of Patents, Designs & Trade Marks has just (March 12, 2012) issued an order granting a compulsory license to patents on the cancer drug sorafenib/Nexavar, in the matter of NATCO Vs. BAYER. A copy of the decision is attached below.

Continue Reading →

KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)

Posted on by KEI Staff

KEI has provided an affidavit in an India compulsory licensing dispute involving Natco and Bayer, for patents on the cancer drug sorafenib (sold by Bayer under the brand name Nexavar).

bayer_logo.gifThe Bayer price for sorafenib/Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. In 2010, per capita income in India was $1,330.

Continue Reading →

2008 May 14 Cable: Poland wants to cap drug cost effectiveness at 3x GDP/pop. Pfizer wants 6x

Posted on by James Love

September 3, 2011 From KEI staff review of Wikileaks cables (/wikileaks) On May 14, 2008, The US Embassy in Warsaw sent a cable that discussed additions to the list of pharmaceutical products reimbursed by the government. A few highlights from… Continue Reading →

The Johnson & Johnson Acuvue Compulsory License

Posted on by Anne Mira Guha

In April of 2010, District Judge Timothy J. Corrigan (M.D Florida, Jacksonville division) declined to grant a permanent injunction following a finding that the Johnson & Johnson’s ACUVUE®OASYS contact lens product infringed patents owned by CIBA Vision Corporation, providing another example of, in effect, a judicial compulsory license following the 2006 eBay v. MercExchange case; the judge wrote:

Continue Reading →

Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list

Posted on by James Love

KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,

A full copy of the paper is available in PDF format here.

The following is from the introduction (sans footnotes, which are in the PDF version):

Introduction and Summary

Continue Reading →